The immune system is at the center of a new era in effective strategies to treat cancer leading to significant growth in the immunooncology sector, and the development of competing technologies to further improve patient survival rates.
Essential to the successful development of cancer immunotherapeutics are ex vivo and in vitro assays to:
- Confirm mode of action
- Compare activity with competitors
- Identify lead candidates
- Evaluate and select combinations
At Abzena, we have developed a suite of assays to confirm and select optimally functioning, lead drug candidates for clinical development. Custom-made assays are also offered for very novel immunotherapeutics.